A Phase 4 interventional study of Isoflurane, Sevoflurane or Desflurane and Propofol in Coronary Heart Disease and Cardiovascular Diseases, sponsored by King's College Hospital NHS Trust. Status unknown at 2 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-24.
Sponsored by King's College Hospital NHS Trust · Phase 4, Interventional, and Treatment
The objective of this research proposal is to find out whether comparing the two different anaesthetic maintenance techniques (Propofol vs volatile anaesthetics) in adult patients undergoing heart surgery is practical for the anaesthetist treating the patients and whether it is feasible for the research team to recruit patients and follow them up after the operation.
All patients undergoing heart bypass surgery are given anaesthetics during the operation. There are two types of anaesthetic commonly given to patients undergoing heart bypass surgery.
Propofol is an anaesthetic that is delivered into the patient's vein. Other anaesthetics which are inhaled include Isoflurane, Sevoflurane and Desflurane and these are called volatile anaesthetics. Preliminary studies over the past ten years suggests that maintenance of general anaesthesia using only volatile anaesthetics has the potential to improve health outcomes after bypass surgery, when compared with propofol.
Volatile anaesthetics have been shown to protect the heart, the kidneys and the brain, however results of studies have been inconclusive. Currently both volatile anaesthetics and propofol are used equally in clinical practice in the UK.
4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.
This study's planned enrollment of 50 is below the median of 100 across 2,738 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →King's College Hospital NHS Trust is the lead sponsor of 164 studies on the registry; 54 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients randomised to receive volatile anaesthetics will receive either isoflurane, sevoflurane or desflurane during the surgical procedure.
Drug: Isoflurane, Sevoflurane or Desflurane
Patients randomised to receive propofol will not receive any volatile anaesthetics during the surgical procedure.
Drug: Propofol
The volatile anaesthetic agent will be administered via inhalation, i.e. ventilation through alveolar membrane in lungs) during the maintenance of anaesthesia. During CPB the volatile anaesthetic agent will be administered through the oxygenator oxygen inflow of the CPB machine. The maintenance dose of the volatile anaesthetic agent will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia and blood pressure. The administration of the volatile anaesthetic agent will be started after induction of anaesthesia and it will be ended at the end of surgery, before the patient is transferred to the CCU.
Patients will receive propofol only during the surgical procedure. The maintenance dose of the propofol infusion will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia (titrated to a depth of anaesthesia with BIS 30-60) and mean arterial pressure (MAP) of 50-80mmHg by the treating anaesthetist.
Recruitment rate
To identify whether it is feasible to recruit up to 50 patients across 2 tertiary cardiac surgery centres within approximately 10 months.
Time frame: Collected over the recruitment period of 10 months
To identify barriers to recruitment.
This data will be completed on a screening log.
Time frame: Collected over the recruitment period of 10 months
Feasibility of maintaining follow-up rates of over 95%
This data will be gathered in the trial database.
Time frame: Collected over the recruitment period of 10 months
Assessment of effectiveness of patient identification and screening processes
To record the number of patients screened and potentially eligible for the trial at the two tertiary cardiac surgery centres within a period of 10 months. This data will be gathered on the screening log.
Time frame: Collected over the recruitment period of 10 months
To investigate whether it is feasible to recruit at least 10% of all potentially eligible patients at the two tertiary cardiac surgery centres within a period of 10 months.
This data will be gathered on screening logs and in the randomisation system.
Time frame: Collected over the recruitment period of 10 months
To investigate whether it is feasible to maintain routine data collection and follow up rates greater than 90% over the trial period.
This data will be gathered in the randomisation site and trial database.
Time frame: Collected over the full trial period of 24 months
To investigate whether it is feasible to achieve 95% data collection of Low Cardiac Output Syndrome for the full trial over the trial period.
This data will be gathered in the trial database.
Time frame: Collected over the full trial period of 24 months
To investigate whether it is feasible to achieve 95% data collection of Myocardial injury, assessed by ischaemic serum markers: hsTnT, MyC, for the full trial over the trial period.
This data will be gathered in the trial database.
Time frame: Preop, 6 hrs after arrival in CCU, and postop day 1 and 2. Collected over the full trial period of 24 months
To investigate whether it is feasible to achieve 90% data collection of MACCE (stroke, non-fatal myocardial infarction, death from any cause) for the full trial over the trial period.
This data will be gathered in the trial database.
Time frame: Data collected at 30 days post op.
To investigate whether it is feasible to achieve 90% data collection of Cardiac related mortality at 30 days for the full trial over the trial period.
This data will be gathered in the trial database.
Time frame: Data collected at 30 days post op.
To investigate whether it is feasible to achieve 90% data collection of Postoperative in hospital atrial fibrillation requiring treatment for the full trial over the trial period.
This data will be gathered in the trial database.
Time frame: Data collected at 30 days post op.
To investigate whether it is feasible to achieve 90% data collection of Acute Kidney Injury (according to Kidney Disease: Improving Global Outcomes guidelines) for the full trial over the trial period.
AKI will be confirmed by a 1.5 - 1.9 increase of serum creatinine from baseline or an absolute value rise of creatine greater than 0.3mg/dl (27mmol/L) from baseline. This data will be gathered in the trial database.
Time frame: Data collected at 30 days post op.
To investigate whether it is feasible to achieve 90% data collection of In-hospital postoperative delirium (assessed by the confusion assessment method) for the full trial over the trial period.
This data will be gathered in the trial database.
Time frame: Data collected at 30 days post op.
To investigate whether it is feasible to achieve 90% data collection of Respiratory complications needing prolonged ventilation (>24 hours) for the full trial over the trial period.
This data will be gathered in the trial database.
Time frame: Data collected at 30 days post op.
To investigate whether it is feasible to achieve 90% data collection of Length of stay in the critical care unit (CCU) for the full trial over the trial period.
This data will be gathered in the trial database.
Time frame: Data collected at 30 days post op.
To investigate whether it is feasible to achieve 90% data collection of Length of hospital stay for the full trial over the trial period.
This data will be gathered in the trial database.
Time frame: Data collected at 30 days post op.
To investigate whether it is feasible to achieve 90% data collection of WHO Disability Assessment Schedule (WHODAS) for the full trial over the trial period.
This data will be gathered in the trial database.
Time frame: Data collected at 30 days post op.
To investigate whether it is feasible to achieve 90% data collection of Quality of Life Questionnaire (Euroqol, EQ-5D-5L) for the full trial over the trial period.
This data will be gathered in the trial database.
Time frame: Data collected at Baseline and 30 days postoperative
To investigate whether it is feasible to achieve 90% data collection of Days alive and at home for the full trial over the trial period.
This data will be gathered in the trial database.
Time frame: Data collected at 30 days postoperative
Plan to share: Yes — Anonymous participant data may be shared with other researchers
No publications or documents are linked to this record.
This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
King's College Hospital NHS Trust